290 related articles for article (PubMed ID: 25350583)
1. Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics.
Joshi V; Shivach T; Yadav N; Rathore AS
Anal Chem; 2014 Dec; 86(23):11606-13. PubMed ID: 25350583
[TBL] [Abstract][Full Text] [Related]
2. Avoiding antibody aggregation during processing: establishing hold times.
Joshi V; Shivach T; Kumar V; Yadav N; Rathore A
Biotechnol J; 2014 Sep; 9(9):1195-205. PubMed ID: 24753430
[TBL] [Abstract][Full Text] [Related]
3. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
[TBL] [Abstract][Full Text] [Related]
4. Application of a high-throughput relative chemical stability assay to screen therapeutic protein formulations by assessment of conformational stability and correlation to aggregation propensity.
Rizzo JM; Shi S; Li Y; Semple A; Esposito JJ; Yu S; Richardson D; Antochshuk V; Shameem M
J Pharm Sci; 2015 May; 104(5):1632-40. PubMed ID: 25757872
[TBL] [Abstract][Full Text] [Related]
5. Reversible NaCl-induced aggregation of a monoclonal antibody at low pH: Characterization of aggregates and factors affecting aggregation.
Bickel F; Herold EM; Signes A; Romeijn S; Jiskoot W; Kiefer H
Eur J Pharm Biopharm; 2016 Oct; 107():310-20. PubMed ID: 27449627
[TBL] [Abstract][Full Text] [Related]
6. Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies.
Ejima D; Tsumoto K; Fukada H; Yumioka R; Nagase K; Arakawa T; Philo JS
Proteins; 2007 Mar; 66(4):954-62. PubMed ID: 17154421
[TBL] [Abstract][Full Text] [Related]
7. Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species.
Zheng S; Qiu D; Adams M; Li J; Mantri RV; Gandhi R
AAPS PharmSciTech; 2017 Jan; 18(1):42-48. PubMed ID: 26340951
[TBL] [Abstract][Full Text] [Related]
8. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
Goldberg DS; Bishop SM; Shah AU; Sathish HA
J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
[TBL] [Abstract][Full Text] [Related]
9. Relation of Colloidal and Conformational Stabilities to Aggregate Formation in a Monoclonal Antibody.
Oyama H; Koga H; Tadokoro T; Maenaka K; Shiota A; Yokoyama M; Noda M; Torisu T; Uchiyama S
J Pharm Sci; 2020 Jan; 109(1):308-315. PubMed ID: 31669120
[TBL] [Abstract][Full Text] [Related]
10. Analytical QbD: development of a native gel electrophoresis method for measurement of monoclonal antibody aggregates.
Pathak M; Dutta D; Rathore A
Electrophoresis; 2014 Aug; 35(15):2163-71. PubMed ID: 24643784
[TBL] [Abstract][Full Text] [Related]
11. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis.
Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R
J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480
[TBL] [Abstract][Full Text] [Related]
12. Technical decision making with higher order structure data: impact of a formulation change on the higher order structure and stability of a mAb.
Gruia F; Du J; Santacroce PV; Remmele RL; Bee JS
J Pharm Sci; 2015 Apr; 104(4):1539-42. PubMed ID: 25270279
[TBL] [Abstract][Full Text] [Related]
13. Hyphenation of size exclusion chromatography to native ion mobility mass spectrometry for the analytical characterization of therapeutic antibodies and related products.
Ehkirch A; Hernandez-Alba O; Colas O; Beck A; Guillarme D; Cianférani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jun; 1086():176-183. PubMed ID: 29684909
[TBL] [Abstract][Full Text] [Related]
14. Analytical Platform for Monitoring Aggregation of Monoclonal Antibody Therapeutics.
Bansal R; Gupta S; Rathore AS
Pharm Res; 2019 Aug; 36(11):152. PubMed ID: 31463609
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Aggregation Kinetics of a Therapeutic Antibody Fragment.
Chakroun N; Hilton D; Ahmad SS; Platt GW; Dalby PA
Mol Pharm; 2016 Feb; 13(2):307-19. PubMed ID: 26692229
[TBL] [Abstract][Full Text] [Related]
16. Effective protocol for the investigation of physicochemical and conformational stability and aggregation kinetics measurements of therapeutic IgG2 monoclonal antibody.
Aboel Dahab A; El-Hag D
J Immunol Methods; 2014 Mar; 405():154-66. PubMed ID: 24530566
[TBL] [Abstract][Full Text] [Related]
17. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
[TBL] [Abstract][Full Text] [Related]
18. Highly concentrated monoclonal antibody solutions: direct analysis of physical structure and thermal stability.
Harn N; Allan C; Oliver C; Middaugh CR
J Pharm Sci; 2007 Mar; 96(3):532-46. PubMed ID: 17083094
[TBL] [Abstract][Full Text] [Related]
19. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements.
Cheng W; Joshi SB; He F; Brems DN; He B; Kerwin BA; Volkin DB; Middaugh CR
J Pharm Sci; 2012 May; 101(5):1701-20. PubMed ID: 22323186
[TBL] [Abstract][Full Text] [Related]
20. Effect of pH and light on aggregation and conformation of an IgG1 mAb.
Mason BD; Schöneich C; Kerwin BA
Mol Pharm; 2012 Apr; 9(4):774-90. PubMed ID: 22300012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
